News BMS suffers further setback in lung cancer No fast approval for immunotherapy combo in first line use.
News AZ looks for advantage over Merck in lung cancer trial AZ rejigs endpoints in key trial of durvalumab
News Novartis, BMS, Janssen unveil R&D deals Companies announce eye-catching R&D plans ahead of conference.
News BMS and PsiOxus to collaborate on cancer-targeting armed vir... BMS to pay up to $936m for NG-348.
News Keytruda set for first line lung cancer use in EU MSD drug will not face competition from BMS rival in this use.
UK & Europe AA Gill takes swipe at NICE in final column NHS initially denied late writer immunotherapy.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
